YDYanling Ding

Yanling Ding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanling Ding has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient journey and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis (IPFLife) in China: a sequential exploratory mixed methods research protocol

    by Hongling Chu, Yanling Ding, Yunxian Zhou, Ping Ji, Bo Yuan, Xi Zhan, Xiaoxi Lu, Ning Liu, Yue Zhang, Bixuan Yan, et al.

    Introduction: Idiopathic pulmonary fibrosis (IPF) is a rare, chronic and progressive lung disease with a significant impact on patients’ quality of life. While much research has focused on disease mechanisms and treatment efficacy, limited attention has been paid to the landscape, unmet needs, patient experiences and quality of life. Understanding these aspects through the patient journey is essential for developing patient-centred therapeutic strategies. Therefore, this study aims to explore the status of diagnosis, treatment, the unmet needs and patient experiences of IPF in China through an analysis of the patient journey using mixed methods research. The findings in this study provide valuable insights to guide drug development, optimise clinical decision-making and support health technology assessments. Methods and analysis: An exploratory sequential mixed methods design will be used in two phases. In the qualitative phase, 50 patients with IPF and 15 experienced physicians will be recruited to complete in-depth interviews. Patient journey and unmet medical needs will be the focus of data collection. Based on the findings of the qualitative study, a structured questionnaire will be developed for the subsequent quantitative study. Data will be collected from 245 patients with IPF to quantitatively analyse critical points in the patient journey, quality of life, unmet needs and treatment expectations. The integration of patient experience data into the drug/intervention development lifecycle in this mixed methods research will enhance the relevance of IPF interventions, optimising disease management strategies and improving patient health outcomes. Ethics and dissemination: The study has been approved by the Peking University Third Hospital Medical Science Research Ethics Committee (2024-188-02). Prior to the study, study information will be provided, and consent will be obtained. Findings in this study will be disseminated in peer-reviewed publications and conferences. Trial registration number: NCT06629623 .


  • Open Access

    Impact of cigarette smoking on rheumatoid arthritis-associated lung diseases: a retrospective case control study on clinical and radiological features and prognosis

    by Jiaqi Ren, Yanling Ding, Jinxia Zhao, Yongchang Sun

    Our study aimed to investigate the clinical and radiological features and prognosis of male smoker patients with rheumatoid arthritis (RA). We consecutively enrolled male inpatients with RA who received chest HRCT during hospitalization in Peking University Third Hospital from Jan 1st, 2012 to August 1st, 2021. 154 male patients with RA were eligible for analysis, of whom 76.6% (n = 118) were current smokers or had a history of cigarette smoking. Compared to never-smokers, smoker patients had more respiratory symptoms, including cough (31.4% vs 5.6%, p = 0.002) and sputum production (26.3% vs 2.8%, p = 0.002), and a higher positive rate of rheumatoid factor (RF) (77.6% vs 58.8%, p = 0.030). A higher percentage of smoker patients showed emphysema (45.8% vs 16.7%, p = 0.002) and signs of lung fibrosis (51/54, 94.4% vs 7/13, 53.8%, p < 0.001) in those with interstitial lung disease (ILD, n = 67) on chest HRCT. The overall survival rate was different between smoker and never-smoker patients (p = 0.031), but instead of cigarette smoking, lung fibrosis on HRCT was the risk factor for survival of our patients. In conclusion, male patients with RA who were current smokers or had a history of cigarette smoking presented more respiratory symptoms and a higher positive rate of RF. They also showed more emphysema and signs of lung fibrosis on chest HRCT. Cigarette smoking impacted on the overall survival as a confounding factor in this cohort of male patients with RA.


  • Bronchiectasis in patients with antineutrophil cytoplasmic antibody-associated vasculitis: a case control study on clinical features and prognosis

    by Jiaqi Ren, Yanling Ding, Jinxia Zhao, Yongchang Sun

    : Bronchiectasis was reported in 2%-40% of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV), but there were no studies on the prevalence, risk factors and impact of AAV...